PubMed Health⌕ Search

PubMed · 11003541

Digital pulse processing: new possibilities in nuclear spectroscopy

Abstract

Digital pulse processing is a signal processing technique in which detector (preamplifier output) signals are directly digitized and processed to extract quantities of interest. This approach has several significant advantages compared to traditional analog signal shaping. First, analyses can be developed which take pulse-by-pulse differences into account, as in making ballistic deficit compensations. Second, transient induced charge signals, which deposit no net charge on an electrode, can be analyzed to give, for example, information on the position of interaction within the detector. Third, deadtimes from transient overload signals are greatly reduced, from tens of micros to hundreds of ns. Fourth, signals are easily captured, so that more complex analyses can be postponed until the source event has been deemed "interesting". Fifth, signal capture and processing may easily be based on coincidence criteria between different detectors or different parts of the same detector. XIAs recently introduced CAMAC module, the DGF-4C, provides many of these features for four input channels, including two levels of digital processing and a FIFO for signal capture for each signal channel. The first level of digital processing is "immediate", taking place in a gate array at the 40 MHz digitization rate, and implements pulse detection, pileup inspection, trapezoidal energy filtering, and control of an external 25.6 micros long FIFO. The second level of digital processing is provided by a digital signal processor (DSP), where more complex algorithms can be implemented. To illustrate digital pulse processing's possibilities, we describe the application of the DGF-4C to a series of experiments. The first, for which the DGF was originally developed, involves locating gamma-ray interaction sites within large segmented Ge detectors. The goal of this work is to attain spatial resolutions of order 2 mm sigma within 70 mm x 90 mm detectors. We show how pulse shape analysis allows ballistic deficit to be significantly reduced in these detectors. A second experiment involves studying exotic nuclei by observing their 1 MeV direct proton decays following implantation in a Si crossed stripe detector at 35 MeV. Whereas the implantation paralyzes analog electronics for almost 10 micros, the DGF allows the study of decay times as short as 1 micros. Initial energy and time resolution results are presented. Finally, we show how the DGF's precise timing and coincidence capabilities lead to significant experimental simplifications in dealing with phoswich detectors, low background counting work, and trace Pb detection by coincident photon detection.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

WK Warburton, M Momayezi, B Hubbard-Nelson, W Skulski. 2000. Digital pulse processing: new possibilities in nuclear spectroscopy. https://doi.org/10.1016/s0969-8043(00)00247-5

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2.

BACKGROUND: Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty risk. METHODS: This study was a prespecified analysis of DANFLU-2, an open-label, individually randomised trial, conducted in Denmark during three consecutive influenza seasons (2022-23, 2023-24, and 2024-25). Adults aged 65 years or older were randomised (1:1) to the HD-IIV or SD-IIV group. The primary endpoint was hospitalisation for influenza or pneumonia. Frailty was defined according to the validated Hospital Frailty Risk Score (HFRS) based on ICD-10 codes within 10 years before randomisation. Participants were stratified into three HFRS categories, namely low (<5 points), intermediate (5-15 points), and high (>15 points) frailty risk. The rVE of HD-IIV versus SD-IIV against the primary endpoint was assessed across prespecified HFRS categories and treating HFRS as a continuous variable. Pearson's chi-square test was used to compare safety events across frailty risk groups and randomisation groups. FINDINGS: Among 332&#x2009;438 randomised participants (mean age 73&#xb7;7 years [SD 5&#xb7;8]; 161&#x2009;538 [48&#xb7;6%] were female), 276&#x2009;173 (83&#xb7;1%) had low frailty risk, 52&#x2009;395 (15&#xb7;8%) had intermediate frailty risk, and 3861 (1&#xb7;2%) had high frailty risk. The primary endpoint of hospitalisation for influenza or pneumonia occurred in 1424 (0&#xb7;5%) of 276&#x2009;173 participants with low frailty risk, 761 (1&#xb7;5%) of 52&#x2009;395 with intermediate frailty risk, and 163 (4&#xb7;2%) of 3861 with high frailty risk (relative risk [RR] for intermediate vs low frailty risk 2&#xb7;8 [95% CI 2&#xb7;6-3&#xb7;1]; RR for high vs low frailty risk 8&#xb7;2 [7&#xb7;0-9&#xb7;6]). HFRS as a continuous variable significantly modified the effect of HD-IIV versus SD-IIV against the primary endpoint with higher rVE estimates with increasing HFRS (pinteraction=0&#xb7;020). The rVE was 0&#xb7;2% (95% CI -10&#xb7;8 to 10&#xb7;2) among those with low frailty risk, 13&#xb7;1% (-0&#xb7;4 to 24&#xb7;8) among those with intermediate frailty risk, and 19&#xb7;9% (-10&#xb7;3 to 42&#xb7;1) among those with high frailty risk. No significant interaction was observed when HFRS was assessed according to the prespecified categorical frailty groups (pinteraction=0&#xb7;17). The proportion of participants with at least one serious adverse event increased across frailty risk groups (13&#x2009;366 [4&#xb7;8%] of 275&#x2009;795 for low frailty risk, 5475 [10&#xb7;5%] of 52&#x2009;315 for intermediate frailty risk, and 777 [20&#xb7;2%] of 3850 for high frailty risk; p<0&#xb7;0001), with similar proportions of serious adverse events in the HD-IIV and SD-IIV groups for each frailty risk group. INTERPRETATION: Among adults aged 65 years or older in Denmark, frailty risk might modify the effects of HD-IIV versus SD-IIV against hospitalisation for influenza or pneumonia, with higher rVE estimates with increasing frailty risk. These findings might support considering high-dose influenza vaccines for frail older adults. However, effect modification was not evident when frailty was assessed using prespecified categorical subgroups, and subgroup-specific estimates were imprecise, with 95% CIs crossing the null. These results should be considered exploratory, warranting further investigation. FUNDING: The DANFLU-2 trial was funded by Sanofi.

Journal Article↗